HCM and heart failure: is your patient at risk?
Rudolf de Boer, MD, PhD
Managing patients with HCM and HF: what’s new in the therapeutic landscape?
Iacopo Olivotto, MD
What is the evidence of SGLT2i in CKD?
Hiddo L. Heerspink, PhD
A call to action: optimizing treatment in CKD
Meg Jardine, MD, PhD
When and how to initiate SGLT2i in CKD
David Wheeler, MB, CHB, MD, FRCP
Primary care role in CKD
Richard Hobbs, MD
4 things to know about CKD and SGLT2i
Tackling risk reduction in ASCVD: Sharing international experience
Matthew Jay Budoff, MD
Lawrence A. Leiter, MD
Peter Libby, MD
P. Gabriel Steg, MD
Prof. Kausik Ray, MBChB, MD, MPhil
Tackling risk reduction in ASCVD: A clinical case
Mechanistic clues to understanding the benefits of icosapent ethyl
Addressing late-breaking data on triglycerides, fibrates and omega-3 FAs
Loading...
We’re glad to see you’re enjoying PACE-CME… but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.